Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart's energy use revealed by new MRI technique in early trial

NCT ID NCT02648009

Knowledge-focused Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new MRI method that uses a special injection called hyperpolarized pyruvate to see how the heart uses energy. Researchers will scan the hearts of up to 112 people with high blood pressure, heart thickening, or heart failure. The goal is to see if this technique can show metabolic activity, which might help doctors better understand and manage heart conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hyperpolarized Pyruvate (13C) Injection
What this could lead to
If successful, this imaging technique could help doctors see how the heart uses energy, potentially leading to better diagnosis and treatment of heart failure.
What could go wrong
This is a very early Phase 1 study focused on imaging, not treatment. It may not lead to any direct patient benefit, and the new method might not work as hoped in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 112 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Apr 2016

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Written consent * Age: 19 to 50 in Arm 1, 30 to 75 in Arm 2 * Group 2A and 2E participants have left-ventricular hypertrophy * Group 2B and 2F participants have diagnosed hypertrophic cardiomyopathy * Group 2C and 2G participants are stable outpatients with NYHA class 1-3 heart failure with evidence of elevated LV mass (LVH), irrespective of LVEF. * Group 2D and 2H participants are stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents Exclusion Criteria * Contraindications to MRI or MRI contrast agents * Hemoglobin ≤ 9.0 gm/dL (only Group 2 participants) * Glomerular filtration rate (based on MDRD Equation) \< 30 ml/min/1.73m2 (only Group 2 participants) * Any condition leading to a life expectancy \<1 year * Medically diagnosed claustrophobia * Have received, or are scheduled to receive, another investigational medicinal product from 1 month prior to 1 month after inclusion in this study * BMI of less than 18.5 or greater than 32 * Group 1: medically diagnosed heart disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure hypertensive disorder hypertrophic cardiomyopathy Hypertrophy type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension Hypertrophy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • St. Michael's Hospital

    NOT_YET_RECRUITING

    Toronto, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    RECRUITING

    Toronto, Ontario, M4N 3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.